QTTB

Q32 BioF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$10.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$5.50

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$2.50

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious and still mostly monitoring-style. Primary sources support a real mid-2026 clinical catalyst and improved runway, but the March 27, 2026 ATM filing adds a live dilution overhang, and the deterministic prior is negative with only middling evidence quality. The stock looks more like a binary trial-and-financing setup than a clean rerating story today [#10-K-2026-03-10] [#8-K-2026-03-27] [#PR-2026-03-10].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-15eventSIGNAL-AA Part B 36-week topline data in mid-2026High impact

Q32 says enrollment is complete at 33 patients, dosing is ongoing, and 36-week topline data from SIGNAL-AA Part B are expected in mid-2026; management also says the study is intended to support advancement into pivotal trials if results are supportive [#10-K-2026-03-10] [#PR-2026-03-10].

2026-12-31catalystATM facility leaves dilution overhang despite improved runwayHigh impact

On March 27, 2026 Q32 entered a Cantor Fitzgerald at-the-market program for up to $14.2 million; the company is not obligated to sell, but the facility adds financing optionality and dilution sensitivity after the February 2026 registered direct offering [#8-K-2026-03-27].

2026-12-31catalystRunway and strategic focus improve only if non-dilutive milestones and readout stay on trackHigh impact

The ADX-097 sale provides $12 million in upfront and near-term milestone payments, including $7 million received at signing, $3 million at the 6-month anniversary, and $2 million upon an earlier milestone or end-2026; together with year-end cash and the February financing, management says this supports operations into 2H27/Q4 2027, but that still depends on execution and does not remove longer-term capital needs [#PR-2025-12-01] [#10-K-2026-03-10] [#PR-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology